American Society of Clinical Oncology
225 Reinekers Lane
Suite 650
Alexandria
Virginia
22314
United States
Tel: 703-299-0150
Fax: 703-299-1044
Website: http://www.asco.org/
Email: asco@asco.org
2045 articles with American Society of Clinical Oncology
-
Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections
5/15/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the latest research from its robust oncology portfolio and pipeline to be presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago from May 31 to June 4.
-
Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting
5/15/2019
Viracta Therapeutics, Inc. announced that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL.
-
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/15/2019
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3rd
-
Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019
5/15/2019
Epic Sciences, Inc. announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois.
-
Amgen Showcases Oncology Pipeline At ASCO 2019
5/15/2019
Amgen announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago, May 31-June 4, 2019.
-
Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting
5/15/2019
Pfizer Inc. (NYSE:PFE) will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4, 2019.
-
New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting
5/15/2019
Merck, known as MSD outside the United States and Canada, announced that new research from the company’s broad oncology clinical development program will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.
-
Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting
5/15/2019
Nektar Therapeutics announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of Clinical Oncology, which is being held from May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.
-
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/15/2019
Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers [15-May-2019] HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , May 15, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced
-
Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019
5/15/2019
Kite, a Gilead Company (Nasdaq: GILD), announced that new data from its cell therapy programs will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from May 31 – June 4, 2019.
-
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
5/15/2019
ImmunoGen, Inc. announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
-
GRAIL Announces Promising New Data with Early Detection Blood Test to be Presented at 2019 American Society of Clinical Oncology Annual Meeting
5/15/2019
GRAIL, Inc., a healthcare company focused on the early detection of cancer, announced that new findings from its Circulating Cell-free Genome Atlas (CCGA) study will be presented in four poster presentations at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
-
Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
5/15/2019
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma
-
AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
5/15/2019
AVEO Oncology announced two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois.
-
Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
4/10/2019
Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer
-
CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain
4/9/2019
Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease
-
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
-
Although there is some slowdown as the FDA moves into the holiday season in late November and into December, there are still upcoming target action dates. Here’s a look at this week’s PDUFA dates.
-
New ASTRO/ASCO/AUA guideline for early-stage prostate cancer supports use of shortened courses of radiation therapy
10/11/2018
Recommendations reflect evidence showing similar early cancer control and side effect rates with hypofractionated treatment, compared to longer courses of conventional radiation
-
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
9/11/2018
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s anti-PD-1 therapy,